UnitedHealth, DexCom, CVS, HCA Healthcare: 4 Must-Have Stocks


The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging population, technological advances, and rising healthcare costs provide the sector with a compelling combination of growth potential and resilience. This market sector’s vast scale and intrinsic appeal create a lucrative landscape for investors proficient at identifying promising opportunities.

UnitedHealth Group: Leveraging the Aging Demographic

UnitedHealth Group Incorporated stock logo
UNHUNH 90-day performance

UnitedHealth Group

$505.34

+4.41 (+0.88%)

(As of 10:52 AM ET)

52-Week Range
$436.38

$554.70

Dividend Yield
1.66%

P/E Ratio
30.89

Price Target
$581.44

A fundamental growth driver within the healthcare sector is the globally expanding population aged 65 and older. As individuals age, they require more healthcare services and products, creating a strong and consistent demand for pharmaceuticals, medical devices, and long-term care solutions. This demographic trend is particularly evident in developed countries, where life expectancies are rising and populations are aging faster.

Overall MarketRank™
4.97 out of 5

Analyst Rating
Moderate Buy

Upside/Downside
14.9% Upside

Short Interest
Healthy

Dividend Strength
Strong

Sustainability
-0.33

News Sentiment
0.16mentions of UnitedHealth Group in the last 14 days

Insider Trading
N/A

Projected Earnings Growth
11.98%

See Full Details

One prominent example of a company capitalizing on this demographic shift is UnitedHealth Group NYSE: UNH. UnitedHealth Group is a diversified healthcare company with a dominant presence in Medicare Advantage, a government-sponsored health insurance program specifically for individuals over 65. 

UnitedHealth Group’s market capitalization exceeds $450 billion, reflecting its robust business model and ability to capitalize on the increasing demand for healthcare services amongst the aging population. The company’s revenues have consistently grown at a compound annual growth rate (CAGR) of over 10% over the past five years, driven by its expansion into Medicare Advantage and its acquisition of Optum. 

The Future of Healthcare: Insights from DexCom’s Growth

DexCom, Inc. stock logo
$113.41

+2.62 (+2.36%)

(As of 10:48 AM ET)

52-Week Range
$74.75

$142.00

P/E Ratio
73.17

Price Target
$140.33

The healthcare sector is undergoing a significant transformation driven by technological innovation. Advancements in telemedicine, artificial intelligence (AI), medical device manufacturing, and gene therapy are revolutionizing healthcare delivery, creating new opportunities for growth and efficiency.

One compelling example of this transformation can be seen in the diabetes management market, where DexCom NASDAQ: DXCM has emerged as a leader in continuous glucose monitoring (CGM) technology. The company exemplifies the potential of technological advancements in healthcare. Its innovative CGM devices empower individuals with diabetes to track their blood glucose levels in real time, providing crucial data for effective health management and reducing the risk of complications.

Overall MarketRank™
4.66 out of 5

Analyst Rating
Moderate Buy

Upside/Downside
24.1% Upside

Short Interest
Healthy

Dividend Strength
N/A

Sustainability
-0.76

News Sentiment
1.50mentions of DexCom in the last 14 days

Insider Trading
Selling Shares

Projected Earnings Growth
25.28%

See Full Details

DexCom has achieved significant revenue growth in recent years, propelled by its market leadership and the expansion of the global diabetes market. Over the past five years, the company has experienced a compound annual growth rate (CAGR) of over 40% in revenue, a testament to the demand for its products and the growing recognition of the importance of CGM in diabetes management. 

The company has a market capitalization of approximately $44 billion. DexCom’s analyst community maintains a consensus rating of “Moderate Buy” with an average price target of $140.33, representing a potential upside of around 26%. The company’s price-to-earnings (P/E) ratio currently stands at 71.45, reflecting investor confidence in DexCom’s growth trajectory and strong market position within the CGM sector.

CVS Health’s Turnaround Strategy and Financial Resilience

CVS Health Co. stock logo
$57.89

+0.36 (+0.63%)

(As of 10:47 AM ET)

52-Week Range
$52.77

$83.25

Dividend Yield
4.59%

P/E Ratio
10.17

Price Target
$75.05

The cost of healthcare services is a persistent challenge facing governments, businesses, and individuals worldwide. Healthcare costs are rising at a rate that outpaces inflation, creating pressure for cost-effective solutions.

Companies focusing on cost containment are well-positioned to benefit from this trend. CVS Health NYSE: CVS exemplifies a strategic approach to cost management within the healthcare industry. The company operates one of the largest pharmacy networks in the United States, serving over 90 million plan members, and offers a diverse portfolio of healthcare services, encompassing pharmacy benefit management (PBM), health insurance, and retail clinics. 

Overall MarketRank™
5.00 out of 5

Analyst Rating
Moderate Buy

Upside/Downside
29.1% Upside

Short Interest
Healthy

Dividend Strength
Strong

Sustainability
-1.25

News Sentiment
0.31mentions of CVS Health in the last 14 days

Insider Trading
Acquiring Shares

Projected Earnings Growth
10.54%

See Full Details

CVS Health’s financials reveal a company in the middle of a turnaround strategy. Despite headwinds over the past twelve months, the company has exhibited a steady growth trajectory, demonstrating its resilience and ability to navigate the cost-sensitive environment within the healthcare sector. 

CVS Health’s analyst community maintains a consensus rating of “Moderate Buy” with an average price target of $75.05, representing a potential upside of 31.3%. The company’s price-to-earnings (P/E) ratio currently stands at 10.11, reflecting a relatively lower valuation than other companies in the sector, which suggests a potential for further growth.

The Impact of Value-Based Care on HCA Healthcare’s Success

HCA Healthcare, Inc. stock logo
HCAHCA 90-day performance

HCA Healthcare

$316.31

+0.96 (+0.30%)

(As of 10:51 AM ET)

52-Week Range
$215.96

$344.20

Dividend Yield
0.83%

P/E Ratio
15.77

Price Target
$326.53

A significant shift is underway in the healthcare delivery model, moving from a fee-for-service system to a value-based care model. Value-based care incentivizes healthcare providers to deliver high-quality care efficiently, focusing on achieving positive health outcomes for patients. This shift creates opportunities for companies focusing on operational efficiency and quality care delivery.

Overall MarketRank™
4.79 out of 5

Analyst Rating
Moderate Buy

Upside/Downside
3.0% Upside

Short Interest
Healthy

Dividend Strength
Weak

Sustainability
-0.92

News Sentiment
0.86mentions of HCA Healthcare in the last 14 days

Insider Trading
Selling Shares

Projected Earnings Growth
10.92%

See Full Details

HCA Healthcare NYSE: HCA is the largest hospital operator in the United States, operating over 185 hospitals and 200 surgical centers. The company strongly focuses on operational efficiency and value-based care, reflecting the evolving demands of the healthcare service sector.

HCA Healthcare’s revenue has grown at a CAGR of over 10% over the past five years, reflecting the strong demand for hospital services and the company’s commitment to operational efficiency. HCA Healthcare’s stock performance has reflected the strong demand for healthcare services, with shares experiencing a 17% year-to-date increase and a 7% rise over the past year. HCA Healthcare’s analyst community projections indicate a bullish outlook, with a high-side price target of $396 representing a 25.4% potential gain.

Navigating the Healthcare Landscape for Long-Term Returns

The healthcare sector’s dynamic nature presents challenges and opportunities for investors. By carefully analyzing the industry’s driving forces, including demographic trends, technological advancements, and the rising pressure for cost-effective solutions, investors can identify companies poised for long-term growth and stability.

While the healthcare sector offers compelling investment opportunities, it’s crucial to remember that diversification is key. You can mitigate risk and enhance returns by investing across various subsectors within the healthcare industry, such as pharmaceuticals, biotechnology, medical devices, and healthcare services. 

Additionally, understanding specific companies’ intricacies, financial performance, and strategic direction is essential for informed investment decisions. By applying these principles and embracing the opportunities presented within the healthcare sector, investors can position themselves for successful and sustainable long-term returns.

Before you consider UnitedHealth Group, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and UnitedHealth Group wasn’t on the list.

While UnitedHealth Group currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company’s CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report



Source link

Content Disclaimer and Copyright Notice
Content Disclaimer

The content provided on this website is sourced from various RSS feeds and other publicly available sources. We strive to ensure the accuracy and reliability of the information, and we always provide source links to the original content. However, we are not responsible for the content’s accuracy or any changes made to the original sources after the information is aggregated on our site.

Fair Use and Copyright Notice

This website may contain copyrighted material, the use of which has not always been specifically authorized by the copyright owner. We believe this constitutes a “fair use” of any such copyrighted material as provided for in section 107 of the US Copyright Law.

In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. If you wish to use copyrighted material from this site for purposes of your own that go beyond fair use, you must obtain permission from the copyright owner.

Leave a Reply

Your email address will not be published. Required fields are marked *